More importantly, our findings showed that AIL significantly enhanced the efficiency of anti-PD-L1 therapy through suppression of Tregs differentiation by inhibiting the c-Jun-PD-L1 axis in melanoma cells, indicating that AIL combined with anti-PD-L1 therapy is a potential promising strategy for melanoma treatment. Here, JUN is linked to melanoma.